ICU Medical, Inc. $ICUI Holdings Reduced by Defilade Capital Management L.P.

Defilade Capital Management L.P. lessened its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 25.4% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 254,291 shares of the medical instruments supplier’s stock after selling 86,454 shares during the quarter. ICU Medical makes up about 4.6% of Defilade Capital Management L.P.’s investment portfolio, making the stock its 6th largest position. Defilade Capital Management L.P.’s holdings in ICU Medical were worth $32,842,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in ICUI. Millennium Management LLC grew its position in shares of ICU Medical by 173.4% during the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after purchasing an additional 690,694 shares in the last quarter. Norges Bank purchased a new stake in shares of ICU Medical in the fourth quarter worth about $58,083,000. Thrivent Financial for Lutherans lifted its position in shares of ICU Medical by 1,604.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after buying an additional 285,648 shares in the last quarter. UBS Group AG lifted its position in shares of ICU Medical by 239.8% in the third quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock worth $46,371,000 after buying an additional 272,782 shares in the last quarter. Finally, Brown Advisory Inc. bought a new position in ICU Medical during the fourth quarter valued at approximately $32,445,000. Institutional investors own 96.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. KeyCorp boosted their price objective on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research report on Tuesday, July 21st. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Needham & Company LLC upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Wednesday, May 27th. Finally, Zacks Research cut shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $172.00.

Insider Buying and Selling at ICU Medical

In other news, Director David C. Greenberg sold 2,424 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the sale, the director owned 7,960 shares in the company, valued at approximately $978,363.60. The trade was a 23.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the sale, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 2.10% of the company’s stock.

ICU Medical Stock Performance

ICUI opened at $168.51 on Monday. The stock has a market cap of $4.21 billion, a PE ratio of 91.09, a PEG ratio of 2.35 and a beta of 0.74. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. The business has a 50 day moving average of $148.01 and a 200-day moving average of $140.23. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $170.81.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, beating the consensus estimate of $1.78 by $0.19. The company had revenue of $525.77 million for the quarter, compared to analyst estimates of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The firm’s revenue was down 12.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Equities research analysts predict that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.